News

REIG JOFRE’s revenues grow 10% and its EBITDA rises 13% and consolidates its international business

• The company maintains its solid growth trajectory with a 10% increase in revenue to 173 million euros and EBITDA of 20.1 million euros, an increase of 13% year-on-year.
• Operating income amounted to 7.7 million euros, an increase of 30%.
• This growth is mainly driven by the steady increase in demand for antibiotics, the solid progress of the dermatological business, the growth of the Forté Pharma brand and the increase in CDMO activity at the Swedish plant.
• The international business consolidated to 56% of revenue, increasing by 13%, especially in European markets where the company has a presence with its own equipment.
• Industrial investment in the first half of 2024 amounted to 8.9 million euros, mainly aimed at increasing productivity and capacity of the Barcelona and Toledo facilities.

Download the full document (PDF)